Tsuyoshi Sasada
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Tsuyoshi Sasada has a total of 39 co-authors. Here are the top co-authors by number of shared publications:
Ryo Tachikawa
5 shared publicationsKeisuke Tomii
Department of Respiratory Medicine, Kobe City Medical Centre General Hospital, Chuo-ku, Kobe, Japan
4 shared publicationsChigusa Shirakawa
Department of Respiratory Medicine, Kobe City Medical Centre General Hospital, Chuo-ku, Kobe, Japan
3 shared publicationsKazuma Nagata
3 shared publications- Chigusa Shirakawa
Department of Respiratory Medicine, Kobe City Medical Center General Hospital
2 shared publications - Keisuke Tomii
Department of Respiratory Medicine, Kobe City Medical Center General Hospital, Kobe, Japan
2 shared publications
Latest Publications
- 23 June 2026
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 14 (10) , 2310-2318.e3
Development and Validation of Clinical Scoring System to Estimate Mucus Plug Presence in Asthma
- 23 June 2026
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 14 (10) , 2310-2318.e3
Development and Validation of Clinical Scoring System to Estimate Mucus Plug Presence in Asthma
- 24 July 2025
- Published by Elsevier in Respiratory Medicine
- Vol. 247, 108269
Association between initial treatment response and prognosis in acute exacerbations of idiopathic pulmonary fibrosis treated with steroid pulse therapy
- 24 July 2025
- Published by Elsevier in Respiratory Medicine
- Vol. 247, 108269
Association between initial treatment response and prognosis in acute exacerbations of idiopathic pulmonary fibrosis treated with steroid pulse therapy
- Open Access
- 1 July 2025
- Published by SAGE Publications in Therapeutic Advances in Infectious Disease
- Vol. 12
Changes in virus-related exacerbations of chronic respiratory diseases before and after the relaxation of COVID-19 infection control measures: a single-centre retrospective study in Japan
Background: Infection prevention and control (IPC) measures during the coronavirus disease 2019 (COVID-19) pandemic have led to a reduction in respiratory viral infections. However, these infections showed a resurgence in the post-COVID-19 era. Respiratory viral infections often exacerbate respiratory diseases. Objectives: This study aimed to determine how the relaxation of IPC measures affects the incidence of virus-related acute exacerbations in various respiratory diseases. Design: A retrospective study conducted at a tertiary care facility. Methods: This study retrospectively assessed data from adult patients aged 18 years and older who visited the emergency department (ED) of a tertiary medical centre in Kobe, Japan, from 1 October 2020 to 12 March 2024. We identified patients who visited because of chronic obstructive pulmonary disease (COPD) exacerbation, asthma exacerbation or acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF) and classified them into two groups based on the pre-relaxation and post-relaxation of IPC measures. The detection rates and respiratory viruses identified using multiplex polymerase chain reaction were compared between the groups. Results: The total number of ED visits was 84,183 involving 129 cases of COPD exacerbation, 156 cases of asthma exacerbation and 68 cases of AE-IPF. Virus-related COPD exacerbations were significantly more frequent after the relaxation of IPC measures than before (7.7% vs 52.5%, p < 0.001). Similarly, virus-related asthma exacerbations occurred significantly more frequently after relaxation than before (39.7% vs 66.7%, p = 0.009). In contrast, no significant difference in the virus-associated AE-IPF was observed before and after relaxation (2.5% vs 5.0%, p = 0.61). Conclusion: Relaxation of IPC measures may increase virus-related exacerbations in COPD and asthma.
- 1 July 2025
- Published by SAGE Publications in Therapeutic Advances in Infectious Disease
- Vol. 12
Open AccessChanges in virus-related exacerbations of chronic respiratory diseases before and after the relaxation of COVID-19 infection control measures: a single-centre retrospective study in Japan
Background: Infection prevention and control (IPC) measures during the coronavirus disease 2019 (COVID-19) pandemic have led to a reduction in respiratory viral infections. However, these infections showed a resurgence in the post-COVID-19 era. Respiratory viral infections often exacerbate respiratory diseases. Objectives: This study aimed to determine how the relaxation of IPC measures affects the incidence of virus-related acute exacerbations in various respiratory diseases. Design: A retrospective study conducted at a tertiary care facility. Methods: This study retrospectively assessed data from adult patients aged 18 years and older who visited the emergency department (ED) of a tertiary medical centre in Kobe, Japan, from 1 October 2020 to 12 March 2024. We identified patients who visited because of chronic obstructive pulmonary disease (COPD) exacerbation, asthma exacerbation or acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF) and classified them into two groups based on the pre-relaxation and post-relaxation of IPC measures. The detection rates and respiratory viruses identified using multiplex polymerase chain reaction were compared between the groups. Results: The total number of ED visits was 84,183 involving 129 cases of COPD exacerbation, 156 cases of asthma exacerbation and 68 cases of AE-IPF. Virus-related COPD exacerbations were significantly more frequent after the relaxation of IPC measures than before (7.7% vs 52.5%, p < 0.001). Similarly, virus-related asthma exacerbations occurred significantly more frequently after relaxation than before (39.7% vs 66.7%, p = 0.009). In contrast, no significant difference in the virus-associated AE-IPF was observed before and after relaxation (2.5% vs 5.0%, p = 0.61). Conclusion: Relaxation of IPC measures may increase virus-related exacerbations in COPD and asthma.
- 14 September 2024
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 64 (suppl 68) , PA681
Association between initial treatment response and prognosis in acute exacerbations of idiopathic pulmonary fibrosis treated with steroid pulse therapy
Background: Steroid pulse therapy is recommended for acute exacerbations of idiopathic pulmonary fibrosis (AE-IPF). While previous studies on AE-IPF have focused on steroid dosages, the treatment course remains unexplored. Our study aims to evaluate the relationship between treatment course and patient prognosis. Methods: We conducted a single-center, retrospective cohort study. Patients showing an increase in the ratio of percutaneous oxygen saturation to inspired oxygen fraction (SpO2/FiO2) following 3 days of steroid pulse therapy were categorized as the "responder group". Those with decreased or unchanged SpO2/FiO2 were labeled the "non-responder group". Our primary outcome was the mortality rate at day 28; secondary outcomes involved a comparative analysis of the SpO2/FiO2 transitions observed on days 1, 4, and 28. Results: The final analysis included 100 AE-IPF patients treated with steroid pulse therapy. The 28-day mortality rate was 14% (8/59) in the responder group and 43% (17/40) in the non-responder group. The Responder group exhibited a significantly lower mortality rate at 28 days. Cox proportional hazards model revealed that the non-responder group (HR: 0.22, CI: 0.10–0.52) and a lower SpO2/FiO2 ratio on day 1 (HR: 0.18, CI:0.06–0.53) were independent predictors of 28-day mortality. At the same time, age and KL-6 levels were not significant factors. Of the responder group, 7 out of 60 patients exhibited a decline in SpO2/FiO2 from day 3 to day 28. Conclusion: The initial response to steroid pulse therapy in AE-IPF patients may be associated with mortality at day 28.
- 14 September 2024
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 64 (suppl 68) , PA681
Association between initial treatment response and prognosis in acute exacerbations of idiopathic pulmonary fibrosis treated with steroid pulse therapy
Background: Steroid pulse therapy is recommended for acute exacerbations of idiopathic pulmonary fibrosis (AE-IPF). While previous studies on AE-IPF have focused on steroid dosages, the treatment course remains unexplored. Our study aims to evaluate the relationship between treatment course and patient prognosis. Methods: We conducted a single-center, retrospective cohort study. Patients showing an increase in the ratio of percutaneous oxygen saturation to inspired oxygen fraction (SpO2/FiO2) following 3 days of steroid pulse therapy were categorized as the "responder group". Those with decreased or unchanged SpO2/FiO2 were labeled the "non-responder group". Our primary outcome was the mortality rate at day 28; secondary outcomes involved a comparative analysis of the SpO2/FiO2 transitions observed on days 1, 4, and 28. Results: The final analysis included 100 AE-IPF patients treated with steroid pulse therapy. The 28-day mortality rate was 14% (8/59) in the responder group and 43% (17/40) in the non-responder group. The Responder group exhibited a significantly lower mortality rate at 28 days. Cox proportional hazards model revealed that the non-responder group (HR: 0.22, CI: 0.10–0.52) and a lower SpO2/FiO2 ratio on day 1 (HR: 0.18, CI:0.06–0.53) were independent predictors of 28-day mortality. At the same time, age and KL-6 levels were not significant factors. Of the responder group, 7 out of 60 patients exhibited a decline in SpO2/FiO2 from day 3 to day 28. Conclusion: The initial response to steroid pulse therapy in AE-IPF patients may be associated with mortality at day 28.
- Open Access
- 3 April 2024
- Published by Wiley in Respirology Case Reports
- Vol. 12 (4) , e01344
Multiple pulmonary nodules with diffuse idiopathic pulmonary neuroendocrine cell hyperplasia and minute pulmonary meningothelial‐like nodules
Key message: A 78‐year‐old woman presented with multiple pulmonary nodules, mixed with solid and ground‐glass nodules. We pathologically confirmed that the multiple pulmonary nodules were a combination of diffuse idiopathic pulmonary neuroendocrine cell hyperplasia (DIPNECH) and multiple pulmonary meningothelial‐like nodules (MPMNs). This is the first case report of concurrent DIPNECH and MPMNs.
- 3 April 2024
- Published by Wiley in Respirology Case Reports
- Vol. 12 (4) , e01344
Open AccessMultiple pulmonary nodules with diffuse idiopathic pulmonary neuroendocrine cell hyperplasia and minute pulmonary meningothelial‐like nodules
Key message: A 78‐year‐old woman presented with multiple pulmonary nodules, mixed with solid and ground‐glass nodules. We pathologically confirmed that the multiple pulmonary nodules were a combination of diffuse idiopathic pulmonary neuroendocrine cell hyperplasia (DIPNECH) and multiple pulmonary meningothelial‐like nodules (MPMNs). This is the first case report of concurrent DIPNECH and MPMNs.
- Open Access
- 11 March 2024
- Published by Wiley in Thoracic Cancer
- Vol. 15 (11) , 934-937
A rare case of tumor‐to‐tumor metastasis from thymic carcinoma to an ovarian mature teratoma
Metastasis from one neoplasm to another is referred to as tumor-to-tumor metastasis (TTM). TTM is rarely observed. Here, we present a patient with TTM from a thymic carcinoma to an ovarian mature teratoma. A 25-year-old woman, diagnosed with unresectable thymic carcinoma, presented with a cyst with a solid tumor component in her right ovary. Laparoscopic cystectomy of the right ovary revealed that the solid tumor was a distant metastasis of the thymic carcinoma in an ovarian mature teratoma. The possibility of malignant transformation of the ovarian mature teratoma was ruled out, enabling accurate staging of the thymic carcinoma. This case emphasizes the need for clinicians to consider TTM and the importance of pathological confirmation of TTM when investigating potential distant metastases.
- 11 March 2024
- Published by Wiley in Thoracic Cancer
- Vol. 15 (11) , 934-937
Open AccessA rare case of tumor‐to‐tumor metastasis from thymic carcinoma to an ovarian mature teratoma
Metastasis from one neoplasm to another is referred to as tumor-to-tumor metastasis (TTM). TTM is rarely observed. Here, we present a patient with TTM from a thymic carcinoma to an ovarian mature teratoma. A 25-year-old woman, diagnosed with unresectable thymic carcinoma, presented with a cyst with a solid tumor component in her right ovary. Laparoscopic cystectomy of the right ovary revealed that the solid tumor was a distant metastasis of the thymic carcinoma in an ovarian mature teratoma. The possibility of malignant transformation of the ovarian mature teratoma was ruled out, enabling accurate staging of the thymic carcinoma. This case emphasizes the need for clinicians to consider TTM and the importance of pathological confirmation of TTM when investigating potential distant metastases.
- Open Access
- 29 November 2023
- Published by Springer Nature in BMC Pulmonary Medicine
- Vol. 23 (1) , 1-9
Incidence and causative agent distribution of viral-induced paediatric asthma exacerbations under strict infection control measures: a single-centre retrospective study in Japan
The prevalence of respiratory viruses in children changed under strict infection control measures during the coronavirus disease 2019 (COVID-19) outbreak. In this study, we investigated the frequency of viral detection in the nasopharynx of paediatric patients with asthma exacerbations requiring hospitalization during the COVID-19 pandemic, as well as the distribution of causative viruses. We included paediatric patients admitted for asthma exacerbations between November 2020 and December 2022 at a single centre in Kobe, Japan. Demographic, clinical, and laboratory data were collected from their medical records and using additional questionnaires. All patients enrolled in this study met the diagnostic criteria for asthma exacerbations outlined in the Japanese Pediatric Guideline for the Treatment and Management of Bronchial Asthma 2020. Statistical differences were calculated using univariate analyses (chi-square or Mann‒Whitney U test). We enrolled 203 children hospitalized for asthma attacks and collected nasopharyngeal samples from 189 patients. The median patient age was 3.0 years. Asthma severity was classified as mild (4.0%), moderate (82.3%), or severe (13.8%). The proportion of viral respiratory infections was 95.2% (180/189). The rate of patients with multiple viral infections was 20.6% (39/189). The most frequently detected pathogens were rhinovirus and enterovirus (RV/EV) at 69.3% (131/189), allowing for duplicate detection, followed by respiratory syncytial virus (RSV) at 28.6% (54/189). We also detected RV/EV almost every month compared to RSV and other viruses. In addition, RV/EV-positive patients were significantly older (p = 0.033), exhibited higher WBC counts (p < 0.001) and higher Eos counts (p < 0.001), had elevated total IgE levels (p < 0.001) and house dust mite-specific IgE levels (p = 0.019), had a shorter duration of hospitalization (p < 0.001), and had a shorter duration of oxygen therapy (p < 0.001). In patients positive for RV/EV, the use of ICSs significantly reduced the severity of the condition (p < 0.001). Even under strict infection control measures, respiratory viruses were detected in the nasopharynx of almost all paediatric patients who had asthma exacerbations requiring hospitalization.
- 29 November 2023
- Published by Springer Nature in BMC Pulmonary Medicine
- Vol. 23 (1) , 1-9
Open AccessIncidence and causative agent distribution of viral-induced paediatric asthma exacerbations under strict infection control measures: a single-centre retrospective study in Japan
The prevalence of respiratory viruses in children changed under strict infection control measures during the coronavirus disease 2019 (COVID-19) outbreak. In this study, we investigated the frequency of viral detection in the nasopharynx of paediatric patients with asthma exacerbations requiring hospitalization during the COVID-19 pandemic, as well as the distribution of causative viruses. We included paediatric patients admitted for asthma exacerbations between November 2020 and December 2022 at a single centre in Kobe, Japan. Demographic, clinical, and laboratory data were collected from their medical records and using additional questionnaires. All patients enrolled in this study met the diagnostic criteria for asthma exacerbations outlined in the Japanese Pediatric Guideline for the Treatment and Management of Bronchial Asthma 2020. Statistical differences were calculated using univariate analyses (chi-square or Mann‒Whitney U test). We enrolled 203 children hospitalized for asthma attacks and collected nasopharyngeal samples from 189 patients. The median patient age was 3.0 years. Asthma severity was classified as mild (4.0%), moderate (82.3%), or severe (13.8%). The proportion of viral respiratory infections was 95.2% (180/189). The rate of patients with multiple viral infections was 20.6% (39/189). The most frequently detected pathogens were rhinovirus and enterovirus (RV/EV) at 69.3% (131/189), allowing for duplicate detection, followed by respiratory syncytial virus (RSV) at 28.6% (54/189). We also detected RV/EV almost every month compared to RSV and other viruses. In addition, RV/EV-positive patients were significantly older (p = 0.033), exhibited higher WBC counts (p < 0.001) and higher Eos counts (p < 0.001), had elevated total IgE levels (p < 0.001) and house dust mite-specific IgE levels (p = 0.019), had a shorter duration of hospitalization (p < 0.001), and had a shorter duration of oxygen therapy (p < 0.001). In patients positive for RV/EV, the use of ICSs significantly reduced the severity of the condition (p < 0.001). Even under strict infection control measures, respiratory viruses were detected in the nasopharynx of almost all paediatric patients who had asthma exacerbations requiring hospitalization.